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Abstract
Background: Cytochrome P450 2C9 (CYP2C9) is involved in metabolism of many important 
drugs and its genotype variations is thought to affect drug efficacy and the treatment process. 
Aim: The aim of this study was to assess the distribution of CYP2C9 allele and genotypic variants 
in Sistani ethnic group, living in Gorgan, South East of Caspian Sea and North East of Iran. 
Subjects and Methods: This study included 140 Sistani, referred to the health center of Gorgan. 
CYP2C9 genotyping was carried out by Polymerase Chain Reaction -Restriction Fragment 
Length Polymorphism technique. Results: The allele frequency of CYP2C9*1, CYP2C9*2 and 
CYP2C9*3 was 76.1%, 16.1% and 7.8%, respectively. The frequency of CYP2C9*1/*1,CYP2C9*1/*2, 
CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes was 53.9%, 22.1%, 11.4%, 
2.9%, 4.3% and nil, respectively. Conclusions: Our findings demonstrate that different genotypes 
of CYP2C9 may influence the pharmacokinetics of some drugs. Determining the pharmacokinetic 
effects of CYP2C9 genotypes may help physicians choose optimal dosage of some drugs for 
treatment and prevention of their side effects. Since different ethnic groups from all over the 
world use medications, it is necessary to investigate the pharmacokinetic effects of CYP2C9 
genotypes in different populations. 
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Introduction
Cytochrome P450 2C (CYP 2C) subfamily of enzymes 
metabolizes approximately 20–30% of most pharmaceutical 
drugs and CYP2C9 is known as its main isoform [1,2]. This 
enzyme is encoded by a gene located on chromosome 10q24 
which shows genetic polymorphism [3]. Variations during genetic 
polymorphism of this enzyme may change catalytic activity of 
the enzyme in drug response [3,4]. The CYP2C9 allele frequencies 
vary among different populations and many studies on CYP2C9 
polymorphism in different populations have shown a significant 
difference in the frequency of alleles and genotypes [5]. This may 
be the cause of possible ethnic differences in drug response. 
Variations in genotype of enzyme have shown that the effect of 
some genotype is the most acute with S-warfarin metabolism 
when compared to the wild type genotype. Clinical studies have 
also indicated that subjects with the mutated genotypes need 10-
20% and/or 20-50% lower doses of S-warfarin, when compared 
to wild type subjects [5]. CYP2C9 is involved in the metabolism 
of important drugs such as (S)-warfarin, losartan, rosuvastatine, 
tolbutamide, glipizide, glibenclamide, the diuretic torsemide, 
phenytoin, flurbiprofen, ibuprofen and diclofenac [6,7]. The 
mutated alleles of CYP2C9 are CYP2C9*2 and CYP2C9*3, 
CYP2C9*6, CYP2C9*15, and CYP2C9*25, but CYP2C9*2 
and CYP2C9*3 are the most prevalent variants [8,9]. These 
alleles are also the most common variants in white populations 
(CYP2C9*2=0.08–0.14% and CYP2C9*3=0.04–0.16%) while, 
some studies indicated a significantly lower frequency of 
these alleles among Asian and African populations [10,11]. Some 
studies have shown that the CYP2C9*2 allele is considered 
in European, Middle Eastern and Central and South Asian 
populations. This allele was absent or considered at very low 
frequencies in Africa, East Asia, Oceania and the Americas. The 
CYP2C9*3 allele shows the highest frequency in the European 
and Central/South Asian populations [12]. Some other studies 
have revealed that the frequency of the CYP2C9*3 allele 
among Japanese and Taiwanese populations are 2.1% and 1.7%, 
respectively. Meanwhile, the CYP2C9*2 allele was not detected 
among the Han Chinese, Japanese and Taiwanese populations [13]. 
As mentioned earlier, these alleles may change the catalytic 
activity of CYP2C9 [6] and on the other hand, many studies have 
shown the variations among different ethnic groups. We have 
previously studied the genetic polymorphism of CYP2C9 gene 
among different ethnic groups in Golestan province [14,15]. This 
study aimed to assess the distribution of CYP2C9 allele and its 
genotypic variants in Sistani ethnic group in the city of Gorgan, 
South East of Caspian Sea, and North East of Iran.
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Subjects and Methods
This study involved 140 healthy Sistani (people who speak 
Sistani as native language) who were referred to a health center 
in Gorgan (South East of Caspian Sea, North East of Iran). The 
sample size determined under supervision of statistical expert. 
This study was approved by the Ethical Committee of Research 
Deputy of Golestan University of Medical Sciences. Written 
consent was obtained from all the study subjects. The distribution 
of CYP2C9 allele and its genotypic variants in Sistani ethnic 
group were determined and compared with other populations. 
First, 5 ml of blood was obtained from all the subjects into 
EDTA tubes. Peripheral white blood cells were used for DNA 
extraction by salting-out method [16]. Two times distillated water 
was used to dissolve the extracted DNA. Collected samples were 
stored at -20oC. CYP2C9*1, CYP2C9*2, and CYP2C9*3 alleles 
genotyping were performed by Polymerase Chain Reaction 
(PCR)-Restriction Fragment Length Polymorphism (RFLP) 
technique using Genetix CG palm-thermocycler (India) [17]. The 
PCR was done in a 25μl reaction mixture including: PCR buffer 
(10 mM Tris–HCl, pH 9, 2 mM MgCl2 (Fermentas), 50mM KCl 
(Fermentas), 0.2 mM deoxyribonucleotide triphosphate (dNTP) 
mix, 1 U/μl Taq polymerase (Fermentas), 0.4 μM of each primer 
(Bioneer), 100 ng DNA (Genomic) and two times distillated 
water. Digestion of PCR products (10μl) was performed using 
restriction enzymes (Fermentas), Ava II for CYP2C9*2 and Kpn 
I for CYP2C9*3 at 37 oC for 16 hours. Primer amplification was 
done using the method explained previously by Aithal et al. [18]. 
The PCR amplification conditions for CYP2C9*2 included: 
Initial denaturation(95°C, 10 minutes), number of cycle (45 
cycles at 95°C for 5 seconds), denaturation (67°C, 10 seconds), 
annealing (72°C, 15 seconds), extension and final extension 
(72°C, 5 minutes). The parameters for CYP2C9*3 were 94°C, 
5 minutes.; 33; 94°C, 45 seconds.; 66°C, 45 seconds.; 72°C, 60 
seconds and 72°C, 5 minutes, respectively. 
Figures 1 and 2 show the PCR products before and after 
digestion with the restriction enzymes for CYP2C9*2 and 
CYP2C9*3 genotypes. Agarose gel (3%) was used to perform 
electrophoresis of (Apelex, France) CYP2C9*2 and CYP2C9*3 
DNA fragments. The gel was stained with ethidium bromide, 
and a Polaroid Gel Camera with black and white film was used 
to detect the bands. Detection of CYP2C9*2 and CYP2C9*3 
mutations were done using sense and antisense primers as 
described below:
For CYP2C9*2 detection:
Sense primer: 3’ CAC TGG CTG AAA GAGS CTA ACA GAG 5’





Chi-squared test was carried out to determine and compare the 
allele and genotype frequencies of CYP2C9. The frequency of 
alleles variant was determined using 95% confidence intervals 
(95% CI). Fisher exact test was used to compare the variations 
of allele and genotype frequencies between Sistani ethnic group 
and other populations. The analysis of data was done using 
SPSS version 16.0 and p-value of less than 0.05 was considered 
as statistically significant.
Table 1: CYP2C9 genotype and allele frequencies of the Sistani 
ethnic group
Genotypes Observed frequency (%) 95% CI
CYP2C9*1/*1 59.30 51 – 67.60
CYP2C9*1/*2 22.10 15.10 – 29.10
CYP2C9*1/*3 11.40 6 – 16.80
CYP2C9*2/*2 2.90 0.10 –5.70
CYP2C9*2/*3 4.30 0.90 –7.70
CYP2C9*3/*3 0 0
Total number 100 -
Alleles
CYP2C9*1 76.10 71 – 81.20
CYP2C9*2 16.10 11.70 – 20.50
CYP2C9*3 7.80 4.60 – 11
Total number 100
Figure 1: PCR-RFLP analysis of CYP2C9*2 genotypes. 
Figure 2: PCR-RFLP analysis of CYP2C9*3 genotypes. 
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Southern Iranians (41.21%), [19] but lower in comparison with 
Iranian Turkmen (76.36%), [18] Mongolians in China (93%), [21] 
Japanese (94.7%), [22] Macedonians (79.8%) [27] and Mestizo 
Mexicans (83%). [29] The most frequently observed mutant allele 
was CYP2C9*1/*2 allele (22.1%). Our results showed that 
CYP2C9*1/*3 genotype (11.4%) was higher in the Sistani ethnic 
group compared to the Japanese (5.3%), [22] Macedonians (0%) 
[27] and Mestizo Mexicans (6.8%) [29] [Table 3]. The prevalence 
of CYP2C9*2/*2 genotype (2.9%) was higher than Mongolians 
in China (0%), [21] Japanese (0%), [22] Southern Europeans 
(0.6%) and Mestizo Mexicans (0.4%). [29] The prevalence of 
CYP2C9*2/*3 genotype (4.3%) was higher than Mongolians 
in China (0%), [21] Japanese (0%), [22] Hungarians (1.5%) [26] and 
Mestizo Mexicans (0.7%) [29].
Discussion
Genotype identification is the most important challenges in 
the future. There are different ethnic groups in various areas 
of Iran. Many drugs are metabolized by the cytochrome P450 
2C9 enzyme [7,19]. Decreased metabolism of some drugs may 
be associated with the presence of CYP2C9*2 and CYP2C9*3 
alleles [20–24]. Alteration in CYP 2C9 genetic polymorphism 
may affect drug response and enzyme activity. The results of 
this study showed CYP2C9*1 as the most prevalent allele in 
Results
The distribution of the CYP2C9 alleles and genotype frequencies 
in the Sistani ethnic group are shown in Table 1. The allele 
frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 was 
76.10% (95% CI: 71-81.20), 16.10% (95% CI: 11.70-20.50) 
and 7.80% (95% CI: 4.60-11), respectively. Tables 2 and 3 
demonstrate the differences in allele and genotype frequencies 
between the Sistani ethnic group and other populations using 
the Fisher exact test. Table 2 shows a significant difference 
in CYP2C9*1 allele of the Sistani ethnic group with Iranian 
Turkmen (88%), [18] Southern Iranians (64.88%), [19] Mongolians 
in China (97%), [20,21] Japenese (97.30%), [22-24] Russians (82.7%), 
[25,26] Macedonians (83.10%), [27,28] and Mestizo Mexicans (91%). 
[29] There was also a significant difference in CYP2C9*2 allele 
of this ethnic group with Iranian Turkman (8%), [18] Southern 
Iranians (25.3%), [19] Mongolians in China (0%), [21] Russians 
(10.5%), [25] Macedonians (10.1%), [27] Southeastern Europeans 
(11.3%) [28] and Mestizo Mexicans (5.1%). [29] The results also 
showed that 50.3% of the Sistani subjects had the CYP2C9*1/*1 
genotype. In the meanwhile, 22.1%, 11.4%, 2.9%, 4.3% and 
none of the subjects had CYP2C9*1/*2, CYP2C9*1/*3, 
CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, 
respectively. Table 3 shows that the prevalence of CYP2C9*1/*1 
among the Sistani ethnic group (59.30%) was higher than the 
Table 2: Distribution of CYP2C9 alleles among the Sistani ethnic group and its comparison with other populations
CYP2C9 alleles CYP2C9*1 CYP2C9*2 CYP2C9*3 Ref.
Sistanis (%) 76.1 16.10 7.80 -
Iranian Turkmen (%) 88* 8* 4 (15)
Persians (%) 83 11 6 (15)
Southern Iranian (%) 64.88* 25.34* 9.80 (19)
Saudi Arabian (%) 79.20 11.70 9.10 (20)
Mongolian in China (%) 97* 0* 3* (21)
Japanese (%) 97.30* 0* 2.70* (22)
Greek (%) 78.97 12.90 8.13 (23)
Italian (%) 77.70 12.50 9.70 (24)
Russian (%) 82.70* 10.50* 6.70 (25)
Hungarian (%) 78.70 12.50 8.80 (26)
Macedonian (%) 83.10* 10.10* 6.80 (27)
Southeastern European (%) 79.40 11.30* 9.30 (28)
Mestizo in Mexican (%) 91* 5.10* 3.90* (29)
*p<0.05
Table 3: Distribution of CYP2C9 genotypes among the Sistani ethnic group and its comparison with other populations
CYP2C9 genotypes *1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3 Total sample number Ref.
Sistanis (%) 59.30 22.10 11.40 2.90 4.30 0 140 _
Iranian Turkmen  (%) 76.36* 15.54 7.27 0 0.90 0 110 (15)
Persian (%) 70 14.55 10.91 2.73 1.82 0 110 15)
Southern Iranian (%) 41.21* 37.83* 9.46 1.35 10.13 0 148 (19)
Saudi Arabian (%) 64.10 17.20 13 2.10 2.10 1.60 192 (20)
Mongolian in China (%) 93* 0* 7 0* 0* 0 280 (21)
Japanese (%) 94.70* 0* 5.30* 0* 0* 0 1017 (22)
Greek (%) 62.19 20.14 13.43 1.41 2.83 0 283 (23)
Italian (%) 62 17.20 14.50 2.70 2.20 1.30 360 (24)
Russian (%) 68 18.20 11.30 0.60 1.20 0.30 290 (25)
Hungarian (%) 62 19.50 13.90 2.10 1.50* 1.10 535 (26)
Macedonian (%) 79.80* 18.60 0* 1.60 0* 0 124 (27)
Southeastern European (%) 63 18.70 14.10 0.60* 2.70 0.90 332 (28)
Mestizo Mexican (%) 83* 8.70* 6.80* 0.40* 0.70* 0.20 947 (29)
*p<0.05
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the Sistani ethnic group (76.1%). Table 3 shows significant 
differences in the frequencies of CYP2C9*2 and CYP2C9*3 
allelic variants between different populations. The prevalence 
of CYP2C9*2 in Southern Iranian [25] was higher compared with 
the Sistanis, but the prevalence of CYP2C9*2 in the Sistani 
ethnic group was higher than other ethnic groups [21-22,25,27-29]. The 
prevalence of CYP2C9*3 polymorphism in Sistanis (7.8%) was 
higher than other populations [21-22,29]. Studies have shown that the 
CYP2C9*3 and CYP2C9*2 alleles are responsible for reduction 
of metabolic activity when compared with CYP2C9*1 [1]. A study 
has indicated that the CYP2C9*2 and CYP2C9*3 alleles, have 
been associated with an elevated risk of warfarin over bleeding 
events and anticoagulation [30]. Metabolism of some drugs such 
as glibenclamide and glimepiride may be affected by different 
genetic polymorphisms of CYP2C9 [31-32]. Studies have also 
shown that metabolism of glibenclamide in heterozygous and 
homozygotes subjects with the CYP2C9*3 allele, was decreased 
2.8 and 0.5 folding in comparison to the wild-type genotypes, 
respectively [1,32]. Some other studies on glipizide have revealed 
that homozygotes subjects with the CYP2C9*3 allele may be 
involved in complications of hypoglycemia [33]. The prevalence 
of CYP2C9*1/*1 in the Sistani ethnic group was higher than 
Southern Iranian (41.21%) [19]and lower than Iranian Turkmen 
(76.36%), Mongolian in China (93%), Japanese (94.70%), 
Macedonian (79.80%) and Mestizo Mexican (83%) [15,21-22,27,29]. 
The prevalence of CYP2C9*1/*2 genotype was lower [19] and 
higher [21-22,29] in comparison with other ethnic groups. Our 
results show that CYP2C9*1/*3 genotype was higher [22,27,29] 
than other populations. The prevalence of CYP2C9*2/*2 [21-
22,28-29] and CYP2C9*2/*3 [21-22,26-27,29] genotypes were higher 
than different other populations. In this study, the prevalence 
of CYP2C9*3/*3 genotype showed no significant difference 
when compared with other populations. Numerous studies have 
demonstrated that the frequency of CYP2C9*3/*3 genotype 
is either very low or undetectable [19,23,25,34-39]. Also, variation 
of CYP2C9*3/*3 genotype may affect drug effectiveness in 
some ethnic group. Genetic polymorphisms, especially the 
homozygous with CYP2C9*3 allele, can lead to a significant 
impairment in metabolic activity of CYP2C9 in different ethnic 
groups.
Conclusion
In this study, the genotypic variations of the CYP2C9 allele 
among the Sistani ethnic group was investigated and great 
differences were observed in comparison to other populations. 
Our findings demonstrate that different genotypes of CYP2C9 
may influence the pharmacokinetics of some drugs. Determining 
the pharmacokinetic effects of CYP2C9 genotypes may help 
physicians choose optimal dosage of some drugs for treatment 
and prevention of their side effects. Since different ethnic 
groups from all over the world use medications, it is necessary 
to investigate the pharmacokinetic effects of CYP2C9 genotypes 
in different populations.
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